Ebglyss (Lebrikizumab)

Lebrikizumab is a medicine used to treat moderate to severe eczema (atopic dermatitis). It is given as a shot under the skin. It works by blocking a protein that causes itchy, inflamed skin.

Brand names:Ebglyss
Medication

What people taking Ebglyss (Lebrikizumab) report

Every report comes from a Lived member, sent anonymously.

Have you tried Ebglyss (Lebrikizumab) for Eczema?

NameHow it went

About Ebglyss (Lebrikizumab)

What It's For

Lebrikizumab, sold as Ebglyss, is a prescription injection for moderate to severe atopic dermatitis, the most common type of eczema, which causes dry, intensely itchy, inflamed patches of skin. It is approved for adults and for children 12 and older who weigh at least 40 kg (about 88 pounds). It is meant for people whose eczema is not controlled well enough by prescription creams and ointments, or who should not keep relying on them. It does not replace skin care: moisturizers continue, and steroid creams can still be used alongside it during flares. Lebrikizumab is a biologic, a medicine made from an engineered antibody, and it joins other injectable eczema biologics such as Dupixent (dupilumab) and Adbry (tralokinumab).

How It Works

In atopic dermatitis, part of the immune system called type 2 inflammation is overactive in the skin. One of its main chemical messengers is interleukin-13 (IL-13), which drives itch, redness and thickening, and weakens the skin's protective barrier so that irritants and allergens get in more easily. Lebrikizumab is a monoclonal antibody, a lab-made protein that attaches to one specific target. It binds to IL-13 and stops it from switching on the receptor that carries its inflammatory signal into skin cells. With less of that signal, inflammation settles and the skin has a chance to repair itself. Because it works by calming an ongoing inflammatory process, the improvement builds gradually over weeks rather than overnight.

Dosage & Administration

Lebrikizumab is injected under the skin of the abdomen, thigh or back of the upper arm, using a single-dose prefilled pen or prefilled syringe. Each contains 250 mg. Treatment starts with a loading phase: two injections on the first day and two more two weeks later, then one injection every 2 weeks until about week 16, or longer if the skin needs more time to respond. Once the eczema is well controlled, the prescriber usually moves to one injection every 4 weeks, and the current US label also allows every 8 weeks. After training, adults can inject themselves, and a caregiver can give the injections to a teenager. Rotate injection sites, and avoid skin that is tender, bruised or affected by eczema, as well as the area within 2 inches of the navel. If a dose is missed, give it as soon as possible, then return to the usual schedule. The pens and syringes are stored in the refrigerator in their carton and must not be frozen or shaken. If needed, a dose can stay at room temperature (up to 86°F) for up to 7 days; after that it should be thrown away.

Side Effects

The most common side effect is conjunctivitis, inflammation of the eye and eyelid with redness, itching or swelling. In the main studies it affected about 1 in 10 people in the first 16 weeks, compared with about 3 in 100 on placebo. Most cases were mild to moderate and cleared without stopping treatment. Report new or worsening eye symptoms, especially eye pain or blurred vision, to the prescriber, since a less common inflammation of the cornea (keratitis) can also occur. Redness or soreness at the injection site and shingles (herpes zoster, a painful blistering rash caused by the chickenpox virus) were also more common than with placebo. Serious allergic reactions are uncommon but possible. Stop using lebrikizumab and get emergency help right away for breathing problems or wheezing, swelling of the face, lips, tongue or throat, or fainting or lightheadedness after a dose. Milder signs such as hives or a new itchy rash should also be reported promptly, because someone who has had a serious allergic reaction to it should not take it again.

Interactions & Warnings

Vaccines need planning. Ideally, routine vaccinations are brought up to date before starting. Live vaccines, which contain a weakened form of a germ, should be avoided just before and during treatment because lebrikizumab may change how the body responds to them. Tell anyone giving a vaccine that you take lebrikizumab, so they can check whether it is a live one. Type 2 immunity also helps fight parasitic worm infections. A known worm infection should be treated before starting, and symptoms of one during treatment (for example after travel to an area where they are common) should be reported. Its effect on other medicines has not been formally studied, and the label does not list specific drug interactions. There is not yet enough information to know whether lebrikizumab affects a pregnancy, and like other antibodies it crosses the placenta, mainly late in pregnancy. Anyone pregnant, planning pregnancy or breastfeeding should weigh the options with the prescriber; the manufacturer runs a pregnancy registry that tracks outcomes.

What to Expect

Some people notice less itching within the first few weeks, but the label judges response at about 16 weeks. In two large studies, about a third to two fifths of people using lebrikizumab alone had clear or almost clear skin at 16 weeks, compared with about 1 in 9 on placebo, and roughly half or more had their eczema improve by at least 75%. Itch dropped substantially for 40 to 46% of people, versus about 1 in 8 on placebo. Not everyone responds, and those who do not improve enough by then may need longer treatment or a different option. For people who did respond, the benefit usually lasted. Among them, roughly two thirds to four fifths still had clear or almost clear skin a year later on injections every 2 or 4 weeks, compared with about half of those switched to placebo. That difference is why the medicine is generally continued at a less frequent maintenance dose rather than stopped once the skin clears. Eczema is a long-term condition, and flares can still happen, so moisturizers and a plan for flares remain part of care. Follow-up visits check skin response, eye symptoms and whether the dosing interval can be stretched.

Questions to Ask Your Doctor

  1. 1.Why is lebrikizumab a good fit for me compared with Dupixent, Adbry or other eczema treatments?
  2. 2.How will we decide at around 16 weeks whether it is working, and what happens if it is not?
  3. 3.Can I eventually move to injections every 4 or 8 weeks, and what would make that possible?
  4. 4.Are my vaccines up to date, and which ones should I get before I start?
  5. 5.What should I do if my eyes become red, itchy or painful?

Last reviewed • Oct 2026

Educational content, not medical advice.